Status:
COMPLETED
Study of Nivolumab for Advanced Cancers in India
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Non-Small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This is a study of nivolumab in participants with advanced Non-Small Cell Lung Cancer or Kidney Cancer in India.
Eligibility Criteria
Inclusion
- For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
- Locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy OR advanced renal cell carcinoma (RCC) after prior therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
- Prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to randomization
Exclusion
- Participants with untreated, symptomatic central nervous system (CNS) metastases
- Participants with carcinomatous meningitis
- Participants with active, known or suspected autoimmune disease
- Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
- Other active malignancy requiring concurrent intervention
- Other protocol defined inclusion/exclusion criteria could apply
Key Trial Info
Start Date :
March 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 17 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03444766
Start Date
March 6 2018
End Date
July 17 2019
Last Update
December 4 2020
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Bangalore, India, 560027
2
Local Institution
Bangalore, India, 560072
3
Local Institution
Bengaluru, India, 560054
4
Local Institution
Hyderabad, India, 500034